Taneisha S Scheuermann1, Kimber P Richter1, Nancy A Rigotti2, Sharon E Cummins3, Kathleen F Harrington4, Scott E Sherman5,6, Shu-Hong Zhu3, Hilary A Tindle7, Kristopher J Preacher8. 1. Department of Preventive Medicine and Public Health, University of Kansas School of Medicine, Kansas City, KS, USA. 2. Tobacco Research and Treatment Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 3. Department of Family Medicine and Public Health, and Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA. 4. Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 5. Department of Population Health, New York University School of Medicine, New York, NY, USA. 6. Department of Medicine, VA New York Harbor Healthcare System, New York, NY, USA. 7. Vanderbilt Center for Tobacco, Addictions, and Lifestyle, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 8. Department of Psychology and Human Development, Vanderbilt University, Nashville, TN, USA.
Abstract
AIMS: To estimate the prevalence and predictors of failed biochemical verification of self-reported abstinence among participants enrolled in trials of hospital-initiated smoking cessation interventions. DESIGN: Comparison of characteristics between participants who verified and those who failed to verify self-reported abstinence. SETTINGS: Multi-site randomized clinical trials conducted between 2010 and 2014 in hospitals throughout the United States. PARTICIPANTS: Recently hospitalized smokers who reported tobacco abstinence 6 months post-randomization and provided a saliva sample for verification purposes (n = 822). MEASUREMENTS: Outcomes were salivary cotinine-verified smoking abstinence at 10 and 15 ng/ml cut-points. Predictors and correlates included participant demographics and tobacco use; hospital diagnoses and treatment; and study characteristics collected via surveys and electronic medical records. FINDINGS:Usable samples were returned by 69.8% of the 1178 eligible trial participants who reported 7-day point prevalence abstinence. The proportion of participants verified as quit was 57.8% [95% confidence interval (CI) = 54.4, 61.2; 10 ng/ml cut-off] or 60.6% (95% CI = 57.2, 63.9; 15 ng/ml). Factors associated independently with verification at 10 ng/ml were education beyond high school education [odds ratio (OR) = 1.51; 95% CI = 1.07, 2.11], continuous abstinence since hospitalization (OR = 2.82; 95% CI = 2.02, 3.94), mailed versus in-person sample (OR = 3.20; 95% CI = 1.96, 5.21) and race. African American participants were less likely to verify abstinence than white participants (OR = 0.64; 95% CI = 0.44, 0.93). Findings were similar for verification at 15 ng/ml. Verification rates did not differ by treatment group. CONCLUSIONS: In the United States, high rates (40%) of recently hospitalized smokers enrolled in smoking cessation trials fail biochemical verification of their self-reported abstinence.
RCT Entities:
AIMS: To estimate the prevalence and predictors of failed biochemical verification of self-reported abstinence among participants enrolled in trials of hospital-initiated smoking cessation interventions. DESIGN: Comparison of characteristics between participants who verified and those who failed to verify self-reported abstinence. SETTINGS: Multi-site randomized clinical trials conducted between 2010 and 2014 in hospitals throughout the United States. PARTICIPANTS: Recently hospitalized smokers who reported tobacco abstinence 6 months post-randomization and provided a saliva sample for verification purposes (n = 822). MEASUREMENTS: Outcomes were salivary cotinine-verified smoking abstinence at 10 and 15 ng/ml cut-points. Predictors and correlates included participant demographics and tobacco use; hospital diagnoses and treatment; and study characteristics collected via surveys and electronic medical records. FINDINGS: Usable samples were returned by 69.8% of the 1178 eligible trial participants who reported 7-day point prevalence abstinence. The proportion of participants verified as quit was 57.8% [95% confidence interval (CI) = 54.4, 61.2; 10 ng/ml cut-off] or 60.6% (95% CI = 57.2, 63.9; 15 ng/ml). Factors associated independently with verification at 10 ng/ml were education beyond high school education [odds ratio (OR) = 1.51; 95% CI = 1.07, 2.11], continuous abstinence since hospitalization (OR = 2.82; 95% CI = 2.02, 3.94), mailed versus in-person sample (OR = 3.20; 95% CI = 1.96, 5.21) and race. African American participants were less likely to verify abstinence than white participants (OR = 0.64; 95% CI = 0.44, 0.93). Findings were similar for verification at 15 ng/ml. Verification rates did not differ by treatment group. CONCLUSIONS: In the United States, high rates (40%) of recently hospitalized smokers enrolled in smoking cessation trials fail biochemical verification of their self-reported abstinence.
Authors: Scott E Sherman; Alissa R Link; Erin S Rogers; Paul Krebs; Joseph A Ladapo; Donna R Shelley; Yixin Fang; Binhuan Wang; Ellie Grossman Journal: Am J Prev Med Date: 2016-10 Impact factor: 5.043
Authors: Sharon E Cummins; Anthony C Gamst; Kendra Brandstein; Gregory B Seymann; Hillary Klonoff-Cohen; Carrie A Kirby; Elisa K Tong; Edward Chaplin; Gary J Tedeschi; Shu-Hong Zhu Journal: Am J Prev Med Date: 2016-10 Impact factor: 5.043
Authors: Nancy A Rigotti; Susan Regan; Douglas E Levy; Sandra Japuntich; Yuchiao Chang; Elyse R Park; Joseph C Viana; Jennifer H K Kelley; Michele Reyen; Daniel E Singer Journal: JAMA Date: 2014-08-20 Impact factor: 56.272
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: R E Glasgow; J P Mullooly; T M Vogt; V J Stevens; E Lichtenstein; J F Hollis; H A Lando; H H Severson; K A Pearson; M R Vogt Journal: Addict Behav Date: 1993 Sep-Oct Impact factor: 3.913
Authors: Yee Tak Derek Cheung; Jessica Pui Kei Leung; Chelsia Ka Ching Cheung; William Ho Cheung Li; Man Ping Wang; Tai Hing Lam Journal: Trials Date: 2016-07-26 Impact factor: 2.279
Authors: Megan E Piper; Jessica W Cook; Tanya R Schlam; Douglas E Jorenby; Stevens S Smith; Linda M Collins; Robin Mermelstein; David Fraser; Michael C Fiore; Timothy B Baker Journal: Ann Behav Med Date: 2018-09-13
Authors: Neal L Benowitz; John T Bernert; Jonathan Foulds; Stephen S Hecht; Peyton Jacob; Martin J Jarvis; Anne Joseph; Cheryl Oncken; Megan E Piper Journal: Nicotine Tob Res Date: 2020-06-12 Impact factor: 4.244
Authors: Gina R Kruse; Vaibhav Thawal; Himanshu A Gupte; Leni Chaudhuri; Sultan Pradhan; Sydney Howard; Nancy A Rigotti Journal: Nicotine Tob Res Date: 2020-03-16 Impact factor: 4.244
Authors: Lorraine S Lathen; Monique L Plears; Emile L Shartle; Karen L Conner; Michael C Fiore; Bruce A Christiansen Journal: Prev Med Rep Date: 2020-07-09